What is the trial about?
The Celeste Light for PD Trial features a non-invasive device that recently
received Breakthrough Device designation from FDA for treating Parkinson’s disease.
If this trial is successful, Celeste could make a major difference in managing non-motor and motor symptoms, and improving overall function
on top of current best medical care.
Participants from anywhere across the country with an internet connection
can apply and will be evaluated via video conference in the most natural and accurate setting — their homes. The trial features a specialized light therapy device that should be used daily for one hour in the evening for six months. Participants can do normal activities like sitting, watching TV, eating, reading, or using a computer
while using the Celeste device.
The device is convenient, non-invasive, and can be used with current medical care. The device is safe to use, and the trial will not increase the risk for COVID-19 infection. The treatment is a minimal risk.
Who’s running the trial?
The Celeste Light for PD trial is a partnership between the Center for Health + Technology at the University of Rochester (CHeT) and PhotoPharmics. CHeT conducts clinical trials across the world aimed at improving the lives of people with Parkinson’s. Since its beginning over 30 years ago, CHeT has reshaped the way we do clinical trials which has led to more effective treatments for Parkinson's. Learn more at chet.urmc.edu.
PhotoPharmics is a privately held, clinical-stage medical device company developing
next-generation treatments for treating neurodegenerative diseases. The founders of the company have 30+ years of research and experience in this field and have previously developed specialized light solutions now widely used—to regulate circadian rhythms in seasonal affective disorder, sleep disorders, anxiety, and depression (acquired by Philips-Respironics in 2007).
Drawing from research and recent trials, PhotoPharmics is developing applications of specialized light across several neurodegenerative diseases, beginning with Parkinson’s disease. The company aims to make a clinically meaningful difference in patients’ lives by delivering safe and effective non-invasive treatments. Investor inquiries are welcomed.
Learn more at www.photopharmics.com.
The Celeste Light for PD Trial consists of four video conference visits during six months with a cap of only 300 participants. Act today to see if you qualify.